EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Study Primary Endpoint Met in AURA-2, a Phase 3 Clinical Study of Bevacizumab EB12-20145P (HLX04-O) for the Treatment of Ophthalmic Diseases

2026.06.16

Essex Bio-Technology (1061.HK) 2025 Annual Results at a glance

2026.03.23

Essex Bio-Technology Reports Robust Results for FY2025. Turnover Soars 8.6% to HK$1814 million. Net Profit up 3.5% to HK$ 318.1 million. Total Dividend Increases by 16.7% to HK14 Cents per Share. Multiple Regulatory Approvals and Strategic Collaborations Strengthened Market Position.

2026.03.23

Date

Title

2026-06-16

Study Primary Endpoint Met in AURA-2, a Phase 3 Clinical Study of Bevacizumab EB12-20145P (HLX04-O) for the Treatment of Ophthalmic Diseases

2026-03-23

Essex Bio-Technology (1061.HK) 2025 Annual Results at a glance

2026-03-23

Essex Bio-Technology Reports Robust Results for FY2025. Turnover Soars 8.6% to HK$1814 million. Net Profit up 3.5% to HK$ 318.1 million. Total Dividend Increases by 16.7% to HK14 Cents per Share. Multiple Regulatory Approvals and Strategic Collaborations Strengthened Market Position.

2026-02-10

EssexBio Bolsters Commitment to Ophthalmology Innovation at APAO 2026 in Hong Kong

2026-01-22

EssexBio to Participate in APAO 2026 and Showcase Key Ophthalmology Assets

2025-12-17

EssexBio Forms Strategic Cooperation with Kenvue for Motrin®, Tylenol® and Rhinocort®

2025-11-21

Essex Bio-Technology establishes strategic collaboration with Biosparc Signs MOU with SIPIPO and Biosparc on International Innovation Accelerator

2025-08-26

Essex Bio-Technology (1061.HK) 2025 Interim Results at a glance

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT